Clinical trials: Epithelial Ovarian Cancer
Carcinoma, Ovarian Epithelial, Low Grade Serous Adenocarcinoma of Ovary
Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)
This is an Italian, multicenter, randomized, open-label phase III trial which will evaluate if Letrozole is superior to standard adjuvant chemotherapy in patients with hormone receptor positive low-grade serous epithelial…
- Trial name
- LEPRE (NCT05601700)
- Testing
- Letrozole tablets, carboplatin AUC 5 and paclitaxel 175 mg/m2
- Where
- 19 sites in Italy
- Volunteers
- 132 people
- Sponsor
- Ente Ospedaliero Ospedali Galliera
Cervical Cancer, Endometrial Cancer
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
This research study is evaluating a drug called avastin in combination with standard radiation as a possible treatment for treatment for recurrent pelvic-confined gynecological cancer (i.e.
- Conditions
- Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Vaginal Cancer
- Trial name
- NCT00545792
- Testing
- Avastin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Dana-Farber Cancer Institute
Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV
Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer
This trial assessed the effect of treatment with CS-1008 in combination with paclitaxel/carboplatin on response in patients with locally advanced or metastatic ovarian cancer.
- Trial name
- NCT00945191
- Testing
- CS-1008, Paclitaxel, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Daiichi Sankyo
Solid Tumor
A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors
The proposed clinical study is a Phase 1/2a trial to investigate the safety, tolerability, pharmacokinetics and clinical activity of anti-HLA-G CAR-T cells IVS-3001 administered to subjects with previously treated, locally…
- Trial name
- NCT05672459
- Testing
- Single Injection of IVS-3001- Anti - HLA-G CAR-T cells, Fludarabine phosphate, Cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer, Gastro-Intestinal Cancer
Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program
This study evaluates physical performance in cancer outpatients during a multimodal therapy. Half of the patients will receive physical exercise und nutrition program in combination with a specially formulated whey protein…
- Conditions
- Lung Cancer, Gastro-Intestinal Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT02585362
- Testing
- physical exercise, nutrition counseling, whey protein supplement
- Where
- Switzerland
- Volunteers
- 52 people
- Sponsor
- Kantonsspital Winterthur KSW
Colorectal Neoplasms, Stomach Neoplasms
Proteomic Analysis of HLA Complex in Solid Cancers: Breast, Ovary, Colon, Rectum, Stomach, and Pancreas
The purpose of this study is to evaluate the presence of proteins in solid tumors which may lead to an immune response
- Conditions
- Colorectal Neoplasms, Stomach Neoplasms, Pancreatic Neoplasms, Breast Neoplasms
- Trial name
- NCT00419627
- Where
- Israel
- Volunteers
- 160 people
- Sponsor
- Hillel Yaffe Medical Center
Pancreatic Cancer, Colo-rectal Cancer
Prehabilitation in High-risk Oncologic Surgery
The goal of this clinical study is to learn whether a prehabilitation program can improve recovery after major abdominal surgery in adults with cancer who are receiving treatment before surgery.
- Conditions
- Pancreatic Cancer, Colo-rectal Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT07638410
- Testing
- Multidisciplinary Prehabilitation Program
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Fox Chase Cancer Center
Adnexal Mass
A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants
The objective of this project is to validate the sensitivity, specificity, positive predictive value and negative predictive values of the AMRA blood test for assessing risk of cancer in women at high risk for ovarian cancer, due…
- Trial name
- OVAnex (NCT04487405)
- Testing
- OVAnex
- Where
- 9 sites in United States
- Volunteers
- 721 people
- Sponsor
- Aspira Women's Health
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Ovarian Neoplasms Malignant (Excl Germ Cell), Peritoneal Carcinoma
Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer
Epithelial ovarian cancer (EOC) is the leading cause of gynecological malignancy-related deaths worldwide and is a substantial health threat to women.
- Conditions
- Ovarian Neoplasms Malignant (Excl Germ Cell), Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- Trientine (NCT03480750)
- Testing
- trientine dihydrochloride, pegylated liposomal doxorubicin, carboplatin
- Volunteers
- 18 people
- Sponsor
- National Cheng-Kung University Hospital
Low Grade Serous Carcinoma
Ribociclib and Letrozole Treatment in Ovarian Cancer
The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian tube or peritoneum.
- Trial name
- NCT03673124
- Testing
- Ribociclib, Letrozole
- Where
- 27 sites in United States
- Volunteers
- 51 people
- Sponsor
- Gynecologic Oncology Group
Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
This study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
- Trial name
- RAMP 201 (NCT04625270)
- Testing
- avutometinib (VS-6766), avutometinib (VS-6766) and defactinib
- Where
- 47 sites in United States, Belgium and 5 more
- Volunteers
- 225 people
- Sponsor
- Verastem, Inc.
Breast Cancer, Ovarian Cancer
Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation
Despite relevant clinical and/or familial presentations suggesting a hereditary predisposition (early-onset, multiple primary tumors, familial aggregation), targeted genomic analysis based on the phenotype are often non…
- Conditions
- Breast Cancer, Ovarian Cancer, Colorectal Cancer, Pediatric Cancers
- Trial name
- PANEL (NCT02664389)
- Testing
- Genetic analysis
- Where
- France
- Volunteers
- 289 people
- Sponsor
- University Hospital, Rouen
Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer
Phase II trial to study the effectiveness of fenretinide in treating patients who have recurrent or metastatic ovarian epithelial or primary peritoneal cancer.
- Conditions
- Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer
- Trial name
- NCT00026091
- Testing
- fenretinide, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Recurrent Gynecological Cancer, Metastatic Cervical Cancer
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
This research study is evaluating the safety and effectiveness of 2 immunotherapy drugs in combination with radiation therapy as a possible treatment for recurrent or metastatic gynecologic cancer.
- Conditions
- Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer, Metastatic Vaginal Cancer
- Trial name
- NCT03277482
- Testing
- Durvalumab, Tremelimumab, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Dana-Farber Cancer Institute
Platinum-resistant Ovarian Cancer
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants…
- Trial name
- NCT07226427
- Testing
- MEN2501
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 100 people
- Sponsor
- Stemline Therapeutics, Inc.
Solid Tumors, Ovarian Cancer
A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours
ALM201/0001 is a Phase I, open-label, dose-escalation study of the safety, tolerability and pharmacokinetics (PK) of ALM201. Part 1 will be a dose-escalation study.
- Trial name
- NCT03427073
- Testing
- ALM201
- Where
- 3 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Almac Discovery
Fallopian Tube Cancer, Ovarian Cancer
Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- AGO-OVAR9 (NCT00052468)
- Testing
- TCG, TC
- Where
- 17 sites in Denmark, France and 2 more
- Volunteers
- 1,742 people
- Sponsor
- AGO Study Group
Platinum-sensitive Ovarian Cancer (UPGRADE-A)
Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer
Phase 1 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks in combination with Carboplatin in participants with high-grade serous…
- Trial name
- UPGRADE (NCT04907968)
- Testing
- XMT-1536 (Upifitamab Rilsodotin), Carboplatin
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Mersana Therapeutics